$KRYS
Krystal Biotech, Inc. Stock $krys

$krys Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000171127921000006 Filed on March 01, 2021

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.810M	$6.470M	$1.420M
YoY Change	27.46%	55.53%	246.34%
% of Gross Profit
Research & Development	$4.350M	$15.62M	$2.800M
YoY Change	55.36%	101.21%	156.88%
% of Gross Profit
Depreciation & Amortization	$340.0K	$1.090M	$60.00K
YoY Change	466.67%	673.05%	500.0%
% of Gross Profit
Operating Expenses	$6.150M	$22.08M	$4.220M
YoY Change	45.73%	184.51%	181.33%
Operating Profit		-$22.08M
YoY Change		85.31%
Interest Expense	$800.0K	$2.990M	$510.0K
YoY Change	56.86%	190.29%	363.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.360M	-$19.09M	-$3.710M
YoY Change	44.47%	75.3%	166.91%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.360M	-$19.09M	-$3.710M
YoY Change	44.47%	75.28%	166.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$309.1K	-$1.201M	-$273.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$193.7M	$193.7M	$111.8M
YoY Change	73.3%	73.26%	125.32%
Cash & Equivalents	$187.5M	$187.5M	$103.7M
Short-Term Investments	$6.171M	$6.200M	$8.091M
Other Short-Term Assets	$2.200M	$2.200M	$900.0K
YoY Change	144.44%	144.44%	4636.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$195.9M	$195.9M	$112.7M
YoY Change	73.88%	73.82%	125.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.475M	$11.20M	$3.014M
YoY Change	181.19%	273.33%	1407.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$500.0K	$500.0K
YoY Change
Other Assets	$1.462M	$1.500M	$452.0K
YoY Change	223.45%	200.0%
Total Long-Term Assets	$13.14M	$13.10M	$3.466M
YoY Change	279.2%	285.29%	1633.0%
TOTAL ASSETS
Total Short-Term Assets	$195.9M	$195.9M	$112.7M
Total Long-Term Assets	$13.14M	$13.10M	$3.466M
Total Assets	$209.0M	$209.0M	$116.1M
YoY Change	80.01%	80.02%	131.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.021M	$700.0K	$888.0K
YoY Change	14.98%	-22.22%	360.1%
Accrued Expenses	$2.500M	$2.500M	$1.500M
YoY Change	66.67%	66.67%	275.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.327M	$3.300M	$2.596M
YoY Change	28.16%	26.92%	305.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.800M	$2.800M	$294.0K
YoY Change	852.38%	833.33%
Total Long-Term Liabilities	$2.800M	$2.800M	$294.0K
YoY Change	852.38%	833.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.327M	$3.300M	$2.596M
Total Long-Term Liabilities	$2.800M	$2.800M	$294.0K
Total Liabilities	$6.109M	$6.100M	$2.890M
YoY Change	111.38%	110.34%	351.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.05M		-$19.96M
YoY Change	95.64%		120.06%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$202.9M	$202.9M	$113.2M
YoY Change
Total Liabilities & Shareholders Equity	$209.0M	$209.0M	$116.1M
YoY Change	80.01%	80.02%	131.7%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$5.360M	-$19.09M	-$3.710M
YoY Change	44.47%	75.28%	166.91%
Depreciation, Depletion And Amortization	$340.0K	$1.090M	$60.00K
YoY Change	466.67%	673.05%	500.0%
Cash From Operating Activities	-$7.000M	-$18.69M	-$3.520M
YoY Change	98.86%	97.88%	65.26%
INVESTING ACTIVITIES
Capital Expenditures	-$2.280M	$6.399M	-$1.300M
YoY Change	75.38%	186.44%	712.5%
Acquisitions
YoY Change
Other Investing Activities	$1.690M	$1.410M	-$2.460M
YoY Change	-168.7%	-117.43%
Cash From Investing Activities	-$590.0K	-$4.991M	-$3.760M
YoY Change	-84.31%	-51.65%	2250.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$107.5M
YoY Change		45.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.0K	$107.5M	64.29M
YoY Change	-99.53%	45.61%	-9417.39%
NET CHANGE
Cash From Operating Activities	-7.000M	-$18.69M	-3.520M
Cash From Investing Activities	-590.0K	-$4.991M	-3.760M
Cash From Financing Activities	300.0K	$107.5M	64.29M
Net Change In Cash	-7.290M	$83.84M	57.01M
YoY Change	-112.79%	55.04%	-2013.09%
FREE CASH FLOW
Cash From Operating Activities	-$7.000M	-$18.69M	-$3.520M
Capital Expenditures	-$2.280M	$6.399M	-$1.300M
Free Cash Flow	-$4.720M	-$25.09M	-$2.220M
YoY Change	112.61%	114.82%	12.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001711279
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38210
CY2020	dei	Entity Registrant Name EntityRegistrantName	Krystal Biotech, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1080209
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Wharton Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Pittsburgh
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15203
CY2020	dei	City Area Code CityAreaCode	412
CY2020	dei	Local Phone Number LocalPhoneNumber	586-5830
CY2020	dei	Security12b Title Security12bTitle	Common Stock
CY2020	dei	Trading Symbol TradingSymbol	KRYS
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	595400000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22194752	shares
CY2020	krys	Lease Termination Date LeaseTerminationDate	2035-10-31
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	268269000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187514000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2993000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	6171000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3796000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2195000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	275058000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	195880000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30876000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8475000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	497000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3298000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2709000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1612000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1462000	USD
CY2020Q4	us-gaap	Assets Assets	310844000	USD
CY2019Q4	us-gaap	Assets Assets	209023000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2105000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1021000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	638000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	480000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5109000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1826000	USD
CY2020Q4	krys	Build To Suit Lease Liability Current BuildToSuitLeaseLiabilityCurrent	7600000	USD
CY2019Q4	krys	Build To Suit Lease Liability Current BuildToSuitLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15452000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3327000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3308000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2782000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	18760000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	6109000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19714220	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19714220	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17354310	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17354310	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	363292000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241951000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71214000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39047000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	202914000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310844000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209023000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17936000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19088000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15616000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15063000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6465000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	32999000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	22081000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-32999000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-22081000	USD
CY2020	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	832000	USD
CY2019	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	2993000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32171000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19080000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.71
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18787161	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15901083	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	113226000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107529000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1239000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19088000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	202914000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	118035000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3306000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19088000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1851000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1090000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3272000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1239000	USD
CY2020	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-33000	USD
CY2019	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-67000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1911000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	868000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	934000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1362000	USD
CY2020	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	685000	USD
CY2019	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-116000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	783000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-199000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2305000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	547000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26083000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83844000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187514000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103670000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18690000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14843000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6399000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3205000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8596000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	6867000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	10501000	USD
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	497000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11181000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4991000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118019000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107525000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118019000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107525000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80755000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9697000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187514000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	681000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	911000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3066000	USD
CY2020	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	131000	USD
CY2019	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	271300000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, construction in progress, and the valuation allowance included in the deferred income tax calculation.
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, U.S. Treasury bills, and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	853614	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	420766	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19088000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18787161	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15901083	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.71
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2019	us-gaap	Depreciation Depreciation	748000	USD
CY2020Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	271255000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2020Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	271262000	USD
CY2019Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	194172000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	194182000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33244000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9325000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2368000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	850000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30876000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8475000	USD
CY2020	us-gaap	Depreciation Depreciation	1500000	USD
CY2020Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1735000	USD
CY2019Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	977000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	642000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	24000	USD
CY2020Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	1486000	USD
CY2019Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	510000	USD
CY2020Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	40000	USD
CY2019Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	40000	USD
CY2020Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	1049000	USD
CY2019Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	263000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12000	USD
CY2020Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	131000	USD
CY2020Q4	krys	Additional Area Of Real Estate Property Leased AdditionalAreaOfRealEstatePropertyLeased	3800	sqft
CY2020Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	10000000	USD
CY2020	krys	Lease Termination Date LeaseTerminationDate	2035-10-31
CY2020Q1	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	USD
CY2020Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10000000	USD
CY2019Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	0	USD
CY2020Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5109000	USD
CY2019Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1826000	USD
CY2020	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2027-02-28
CY2020Q1	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2020Q4	us-gaap	Escrow Deposit EscrowDeposit	1500000	USD
CY2020Q4	krys	Lessor Operating Lease Liability Annual Lease Payments LessorOperatingLeaseLiabilityAnnualLeasePayments	82000	USD
CY2020Q4	krys	Cumulative Escalation Clause Percent CumulativeEscalationClausePercent	0.10
CY2020Q4	krys	Cumulative Escalation Clause Term CumulativeEscalationClauseTerm	P5Y
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2709000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1430000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1464000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1492000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1520000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1555000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16064000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23525000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6383000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3946000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3298000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2782000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3946000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3262000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	638000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	480000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3308000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y4M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	756000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	630000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	68000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	39000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	159500	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.04
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	357089	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.73
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4302000	USD
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72073	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.08
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23750	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.82
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	420766	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.71
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15859000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	891250	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	47.29
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	84285	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.45
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	131125	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.96
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	374117	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	38.24
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	853614	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.31
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16804000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5905000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3100000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2800000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3272000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1239000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1690787	shares
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	34000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1200000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6752000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4008000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11112000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6471000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2632000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1522000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	887000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	604000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-216000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-223000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-625000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-114000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19189000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9934000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	664000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	140000	USD
CY2020Q4	krys	Deferred Tax Assets Build To Suit Lease Liability DeferredTaxAssetsBuildToSuitLeaseLiability	2893000	USD
CY2019Q4	krys	Deferred Tax Assets Build To Suit Lease Liability DeferredTaxAssetsBuildToSuitLeaseLiability	0	USD
CY2020Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1142000	USD
CY2019Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	945000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	123000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	46000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	144000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2311000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	820000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26368000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11983000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22043000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10931000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4325000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1052000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3000	USD
CY2020Q4	krys	Deferred Tax Liabilities Capitalized Construction Costs DeferredTaxLiabilitiesCapitalizedConstructionCosts	2893000	USD
CY2019Q4	krys	Deferred Tax Liabilities Capitalized Construction Costs DeferredTaxLiabilitiesCapitalizedConstructionCosts	0	USD
CY2020Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	954000	USD
CY2019Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	785000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	476000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	261000	USD
CY2020Q4	krys	Deferred Tax Liabilities Unrealized Loss On Marketable Securities DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities	2000	USD
CY2019Q4	krys	Deferred Tax Liabilities Unrealized Loss On Marketable Securities DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities	3000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4325000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1052000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	krys	Ownership Interest Rate Change Over Period OwnershipInterestRateChangeOverPeriod	P3Y

Files In Submission

Name	View Source	Status
0001711279-21-000006-index-headers.html	Edgar Link	pending
R8.htm	Edgar Link	pending
0001711279-21-000006-index.html	Edgar Link	pending
0001711279-21-000006.txt	Edgar Link	pending
0001711279-21-000006-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
krys-20201231.htm	Edgar Link	pending
krys-20201231.xsd	Edgar Link	pending
krys-20201231ex1013_thir.htm	Edgar Link	pending
krys-20201231ex1013_thir001.jpg	Edgar Link	pending
krys-20201231ex1013_thir002.jpg	Edgar Link	pending
krys-20201231ex1013_thir003.jpg	Edgar Link	pending
krys-20201231ex1013_thir004.jpg	Edgar Link	pending
krys-20201231ex1013_thir005.jpg	Edgar Link	pending
krys-20201231ex1013_thir006.jpg	Edgar Link	pending
krys-20201231ex1013_thir007.jpg	Edgar Link	pending
krys-20201231ex1013_thir008.jpg	Edgar Link	pending
krys-20201231ex1013_thir009.jpg	Edgar Link	pending
krys-20201231ex1013_thir010.jpg	Edgar Link	pending
krys-20201231ex1013_thir011.jpg	Edgar Link	pending
krys-20201231ex1013_thir012.jpg	Edgar Link	pending
krys-20201231ex1013_thir013.jpg	Edgar Link	pending
krys-20201231ex1014_four.htm	Edgar Link	pending
krys-20201231ex1014_four001.jpg	Edgar Link	pending
krys-20201231ex1014_four002.jpg	Edgar Link	pending
krys-20201231ex1014_four003.jpg	Edgar Link	pending
krys-20201231ex1014_four004.jpg	Edgar Link	pending
krys-20201231ex1014_four005.jpg	Edgar Link	pending
krys-20201231ex1014_four006.jpg	Edgar Link	pending
krys-20201231ex1015_fift.htm	Edgar Link	pending
krys-20201231ex1015_fift001.jpg	Edgar Link	pending
krys-20201231ex1015_fift002.jpg	Edgar Link	pending
krys-20201231ex1015_fift003.jpg	Edgar Link	pending
krys-20201231ex1015_fift004.jpg	Edgar Link	pending
krys-20201231ex1015_fift005.jpg	Edgar Link	pending
krys-20201231ex1015_fift006.jpg	Edgar Link	pending
krys-20201231ex1015_fift007.jpg	Edgar Link	pending
krys-20201231ex1015_fift008.jpg	Edgar Link	pending
krys-20201231ex1015_fift009.jpg	Edgar Link	pending
krys-20201231ex1016_nort.htm	Edgar Link	pending
krys-20201231ex1016_nort001.jpg	Edgar Link	pending
krys-20201231ex1016_nort002.jpg	Edgar Link	pending
krys-20201231ex1016_nort003.jpg	Edgar Link	pending
krys-20201231ex1016_nort004.jpg	Edgar Link	pending
krys-20201231ex1016_nort005.jpg	Edgar Link	pending
krys-20201231ex1016_nort006.jpg	Edgar Link	pending
krys-20201231ex1016_nort007.jpg	Edgar Link	pending
krys-20201231ex1016_nort008.jpg	Edgar Link	pending
krys-20201231ex1016_nort009.jpg	Edgar Link	pending
krys-20201231ex1016_nort010.jpg	Edgar Link	pending
krys-20201231ex1016_nort011.jpg	Edgar Link	pending
krys-20201231ex1016_nort012.jpg	Edgar Link	pending
krys-20201231ex1016_nort013.jpg	Edgar Link	pending
krys-20201231ex1016_nort014.jpg	Edgar Link	pending
krys-20201231ex1016_nort015.jpg	Edgar Link	pending
krys-20201231ex1016_nort016.jpg	Edgar Link	pending
krys-20201231ex1016_nort017.jpg	Edgar Link	pending
krys-20201231ex1016_nort018.jpg	Edgar Link	pending
krys-20201231ex1016_nort019.jpg	Edgar Link	pending
krys-20201231ex1016_nort020.jpg	Edgar Link	pending
krys-20201231ex1016_nort021.jpg	Edgar Link	pending
krys-20201231ex1016_nort022.jpg	Edgar Link	pending
krys-20201231ex1016_nort023.jpg	Edgar Link	pending
krys-20201231ex1016_nort024.jpg	Edgar Link	pending
krys-20201231ex1016_nort025.jpg	Edgar Link	pending
krys-20201231ex1016_nort026.jpg	Edgar Link	pending
krys-20201231ex1016_nort027.jpg	Edgar Link	pending
krys-20201231ex1016_nort028.jpg	Edgar Link	pending
krys-20201231ex1016_nort029.jpg	Edgar Link	pending
krys-20201231ex1016_nort030.jpg	Edgar Link	pending
krys-20201231ex1016_nort031.jpg	Edgar Link	pending
krys-20201231ex1016_nort032.jpg	Edgar Link	pending
krys-20201231ex1016_nort033.jpg	Edgar Link	pending
krys-20201231ex1016_nort034.jpg	Edgar Link	pending
krys-20201231ex1016_nort035.jpg	Edgar Link	pending
krys-20201231ex1016_nort036.jpg	Edgar Link	pending
krys-20201231ex1016_nort037.jpg	Edgar Link	pending
krys-20201231ex1016_nort038.jpg	Edgar Link	pending
krys-20201231ex1016_nort039.jpg	Edgar Link	pending
krys-20201231ex1016_nort040.jpg	Edgar Link	pending
krys-20201231ex1016_nort041.jpg	Edgar Link	pending
krys-20201231ex1016_nort042.jpg	Edgar Link	pending
krys-20201231ex1016_nort043.jpg	Edgar Link	pending
krys-20201231ex1016_nort044.jpg	Edgar Link	pending
krys-20201231ex1016_nort045.jpg	Edgar Link	pending
krys-20201231ex1016_nort046.jpg	Edgar Link	pending
krys-20201231ex1016_nort047.jpg	Edgar Link	pending
krys-20201231ex1016_nort048.jpg	Edgar Link	pending
krys-20201231ex1016_nort049.jpg	Edgar Link	pending
krys-20201231ex1016_nort050.jpg	Edgar Link	pending
krys-20201231ex1016_nort051.jpg	Edgar Link	pending
krys-20201231ex1016_nort052.jpg	Edgar Link	pending
krys-20201231ex1016_nort053.jpg	Edgar Link	pending
krys-20201231ex1016_nort054.jpg	Edgar Link	pending
krys-20201231ex1016_nort055.jpg	Edgar Link	pending
krys-20201231ex1016_nort056.jpg	Edgar Link	pending
krys-20201231ex1016_nort057.jpg	Edgar Link	pending
krys-20201231ex1016_nort058.jpg	Edgar Link	pending
krys-20201231ex1016_nort059.jpg	Edgar Link	pending
krys-20201231ex1016_nort060.jpg	Edgar Link	pending
krys-20201231ex1016_nort061.jpg	Edgar Link	pending
krys-20201231ex1016_nort062.jpg	Edgar Link	pending
krys-20201231ex1016_nort063.jpg	Edgar Link	pending
krys-20201231ex1016_nort064.jpg	Edgar Link	pending
krys-20201231ex1017_nort.htm	Edgar Link	pending
krys-20201231ex1017_nort001.jpg	Edgar Link	pending
krys-20201231ex1017_nort002.jpg	Edgar Link	pending
krys-20201231ex1017_nort003.jpg	Edgar Link	pending
krys-20201231ex1017_nort004.jpg	Edgar Link	pending
krys-20201231ex1018_nort.htm	Edgar Link	pending
krys-20201231ex1018_nort001.jpg	Edgar Link	pending
krys-20201231ex1018_nort002.jpg	Edgar Link	pending
krys-20201231ex1018_nort003.jpg	Edgar Link	pending
krys-20201231ex1018_nort004.jpg	Edgar Link	pending
krys-20201231ex1018_nort005.jpg	Edgar Link	pending
krys-20201231ex1018_nort006.jpg	Edgar Link	pending
krys-20201231ex1018_nort007.jpg	Edgar Link	pending
krys-20201231ex1018_nort008.jpg	Edgar Link	pending
krys-20201231ex1018_nort009.jpg	Edgar Link	pending
krys-20201231ex1019_nort.htm	Edgar Link	pending
krys-20201231ex1019_nort001.jpg	Edgar Link	pending
krys-20201231ex1019_nort002.jpg	Edgar Link	pending
krys-20201231ex104_emplo.htm	Edgar Link	pending
krys-20201231ex104_emplo001.jpg	Edgar Link	pending
krys-20201231ex104_emplo002.jpg	Edgar Link	pending
krys-20201231ex104_emplo003.jpg	Edgar Link	pending
krys-20201231ex104_emplo004.jpg	Edgar Link	pending
krys-20201231ex104_emplo005.jpg	Edgar Link	pending
krys-20201231ex104_emplo006.jpg	Edgar Link	pending
krys-20201231ex104_emplo007.jpg	Edgar Link	pending
krys-20201231ex104_emplo008.jpg	Edgar Link	pending
krys-20201231ex211_subsi.htm	Edgar Link	pending
krys-20201231ex211_subsi001.jpg	Edgar Link	pending
krys-20201231ex231_conse.htm	Edgar Link	pending
krys-20201231ex231_conse001.jpg	Edgar Link	pending
krys-20201231ex3111.htm	Edgar Link	pending
krys-20201231ex3121.htm	Edgar Link	pending
krys-20201231ex3211.htm	Edgar Link	pending
krys-20201231ex3221.htm	Edgar Link	pending
krys-20201231ex43_descri.htm	Edgar Link	pending
krys-20201231ex43_descri001.jpg	Edgar Link	pending
krys-20201231ex43_descri002.jpg	Edgar Link	pending
krys-20201231ex43_descri003.jpg	Edgar Link	pending
krys-20201231_cal.xml	Edgar Link	unprocessable
krys-20201231_def.xml	Edgar Link	unprocessable
krys-20201231_g1.jpg	Edgar Link	pending
krys-20201231_g2.jpg	Edgar Link	pending
krys-20201231_htm.xml	Edgar Link	completed
krys-20201231_lab.xml	Edgar Link	unprocessable
krys-20201231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRYS
Krystal Biotech, Inc. Stock $krys

2019 Q4 Form 10-K Financial Statement

#000171127921000006 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS Krystal Biotech, Inc. Stock $krys

2019 Q4 Form 10-K Financial Statement

#000171127921000006 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS
Krystal Biotech, Inc. Stock $krys